Abiopharma

🔍 ADAR1 Capital Management, LLC (Executive)

Company: NextCure, Inc. (NXTC)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Common Stock at $4.9723 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 443,266.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 20,000 shares of Common Stock at $5.0 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 463,266.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 20,000 shares of Common Stock at $5.0 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 483,266.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 25,000 shares of Common Stock at $4.8135 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 508,266.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Acquired 100,000 shares of Common Stock at $4.9 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 608,266.00 | transaction_form_type: 4 | Footnotes: F6
• Acquired 77,850 shares of Common Stock at $4.9556 per share (Direct)
  Date: 2026-07-30 | Code: P | equity_swap_involved: 0 | shares_owned_after: 686,116.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Acquired 3,300 shares of Common Stock at $4.9758 per share (Direct)
  Date: 2026-07-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 689,416.00 | transaction_form_type: 4 | Footnotes: F4, F6
• Acquired 25,000 shares of Common Stock at $4.9816 per share (Direct)
  Date: 2026-07-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 714,416.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Acquired 8,003 shares of Common Stock at $4.8 per share (Direct)
  Date: 2026-07-31 | Code: P | equity_swap_involved: 0 | shares_owned_after: 722,419.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F5: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
• F6: The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
• F7: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.